CRISPR Therapeutics AG (CRSP) Total Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Total Current Liabilities data on file, last reported at $136.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 14.1% year-over-year to $136.3 million; the trailing twelve-month figure through Mar 2026 stood at $136.3 million (up 14.1% YoY), and the FY2025 full-year result was $149.1 million, up 69.88% from the prior year.
• Total Current Liabilities fell to $136.3 million in Q1 2026, from $149.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $150.9 million in Q3 2022 to a low of $87.8 million in Q4 2024.
• A 5-year average of $121.1 million and a median of $119.4 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slipped 26.27% in 2023 and jumped 69.88% in 2025, its largest moves.
• Tracing CRSP's Total Current Liabilities over 5 years: stood at $121.1 million in 2022, then slipped by 10.17% to $108.8 million in 2023, then fell by 19.31% to $87.8 million in 2024, then jumped by 69.88% to $149.1 million in 2025, then declined by 8.61% to $136.3 million in 2026.
• Business Quant data shows CRSP's Total Current Liabilities at $136.3 million in Q1 2026, $149.1 million in Q4 2025, and $119.0 million in Q3 2025.